Keros Therapeutics (NASDAQ:KROS) Trading Down 5.7% After Analyst Downgrade

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) traded down 5.7% on Tuesday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics traded as low as $18.12 and last traded at $18.32. 350,670 shares were traded during trading, a decline of 24% from the average session volume of 463,453 shares. The stock had previously closed at $19.42.

KROS has been the subject of a number of other research reports. Scotiabank dropped their price objective on Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating for the company in a research note on Friday. BTIG Research cut Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, December 12th. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating for the company. Wedbush reissued an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Guggenheim lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, Keros Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $81.33.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently made changes to their positions in KROS. Geode Capital Management LLC grew its position in Keros Therapeutics by 6.8% in the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock worth $42,146,000 after acquiring an additional 46,041 shares in the last quarter. Barclays PLC lifted its stake in shares of Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Keros Therapeutics in the 3rd quarter worth approximately $868,000. Point72 DIFC Ltd increased its position in shares of Keros Therapeutics by 9.8% during the 3rd quarter. Point72 DIFC Ltd now owns 19,255 shares of the company's stock valued at $1,118,000 after purchasing an additional 1,715 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after buying an additional 577,220 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

The company has a fifty day moving average of $58.29 and a two-hundred day moving average of $52.50. The company has a market cap of $729.13 million, a PE ratio of -3.46 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company's revenue was up 4750.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) EPS. On average, equities analysts forecast that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.